A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Evofosfamide (Primary) ; Doxorubicin
- Indications Liver cancer
- Focus Adverse reactions
- 03 Jul 2014 Planned initiation date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 04 Jul 2013 Planned initiation date changed from 1 Jul 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 10 Jun 2013 Planned end date changed from 1 Dec 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov.